Literature DB >> 8328791

Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads.

R A Zabinski1, A J Larsson, K J Walker, S S Gilliland, J C Rotschafer.   

Abstract

To prove the utility of antibiotic-removal beads in separating antibiotics from bacterial samples, Escherichia coli ATCC 25922 was exposed to five separate quinolones before and after each was exposed to antibiotic-removal beads. Plates treated with antibiotic solutions that were exposed to beads demonstrated antibiotic removal, and plates treated with antibiotic solutions that were not exposed to beads demonstrated antibiotic carryover. After exposure to beads, fluoroquinolone concentrations decreased from 5 micrograms/ml to 0.14 micrograms/ml (ciprofloxacin), 0.04 micrograms/ml (temafloxacin), < 0.01 microgram/ml (ofloxacin), < 0.01 microgram/ml (sparfloxacin), and 0.02 micrograms/ml (clinafloxacin). These data indicate that antibiotic carryover can be successfully circumvented through the use of antibiotic-removal beads.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328791      PMCID: PMC187972          DOI: 10.1128/AAC.37.6.1377

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Evaluation of new blood culture processing systems.

Authors:  J A Moody; C E Fasching; C J Shanholtzer; D N Gerding; L R Peterson
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

2.  Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.

Authors:  C W Stratton; L S Weeks
Journal:  Diagn Microbiol Infect Dis       Date:  1990 May-Jun       Impact factor: 2.803

3.  In vitro evaluation of the BACTEC resin-containing blood culture bottle.

Authors:  S M Smith; R H Eng
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

4.  Importance of minimizing carry-over effect at subculture in the detection of penicillin-tolerant viridans group streptococci.

Authors:  J Dankert; Y Holloway; W Joldersma; J Hess
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.

Authors:  B J McGrath; E M Bailey; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy.

Authors:  R H Eng; C Cherubin; S M Smith; F Buccini
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

  6 in total
  12 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens.

Authors:  G H Ross; L B Hovde; K H Ibrahim; Y H Ibrahim; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.

Authors:  Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  M L Peterson; L B Hovde; D H Wright; G H Brown; A D Hoang; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

Authors:  M L Peterson; L B Hovde; D H Wright; A D Hoang; J K Raddatz; P J Boysen; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

7.  Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.

Authors:  K J Madaras-Kelly; B E Ostergaard; L B Hovde; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.

Authors:  J M Hyatt; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.

Authors:  Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

Authors:  R A Zabinski; K J Walker; A J Larsson; J A Moody; G W Kaatz; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.